Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Obesity, Fatty Liver and Liver Cancer -

Obesity, Fatty Liver and Liver Cancer

Jun Yu (Herausgeber)

Buch | Softcover
157 Seiten
2019 | Softcover reprint of the original 1st ed. 2018
Springer Verlag, Singapore
978-981-13-4213-4 (ISBN)
CHF 224,65 inkl. MwSt
  • Versand in 10-14 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
This volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field.
This volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. The contents are extensive and comprehensive. It brings important topics in the field all together under one umbrella, from epidemiology and etiology, molecular pathogenesis, cellular biology, epigenetics, immunology, microbiology, animal models to therapeutic approaches and treatments. All the book contributors are leading experts in the field. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field. It may also yield benefits for pharmaceutical companies with regard to drug discovery.

Prof. Jun Yu is Professor in Department of Medicine & Therapeutics, Director of Research Laboratory of Institute of Digestive Disease, Associate Director of State Key Laboratory of Digestive Disease and Faculty of Medicine in The Chinese University of Hong Kong.

Chapter 1. Introduction.- Chapter 2. Epidemiology and etiology of NAFLD and associated HCC.- Chapter 3. Pathogenesis of NASH: How metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease.- Chapter 4. Chemokines and Chemokine Receptors in the Development of NAFLD.- Chapter 5. NAFLD related-HCC: the relationship with metabolic disorders.- Chapter 6. Hepatocellular carcinoma in obesity: Finding a needle in the haystack?.- Chapter 7. Dysregulated epigenetic modifications in the pathogenesis of NAFLD-HCC.- Chapter 8. The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease.- Chapter 9. Microbiota, obesity and NAFLD.- Chapter 10. Autophagy, NAFLD and NAFLD-related HCC.- Chapter 11. Animal models of non-alcoholic fatty liver diseases and its associated liver cancer.- Chapter 12. Current prevention and treatment options for NAFLD.

Erscheint lt. Verlag 6.2.2019
Reihe/Serie Advances in Experimental Medicine and Biology ; 1061
Zusatzinfo 23 Illustrations, color; 1 Illustrations, black and white; XII, 157 p. 24 illus., 23 illus. in color.
Verlagsort Singapore
Sprache englisch
Maße 178 x 254 mm
Themenwelt Medizinische Fachgebiete Innere Medizin Hepatologie
Medizin / Pharmazie Medizinische Fachgebiete Onkologie
Medizin / Pharmazie Studium
Schlagworte GI cancer • hepatocellular carcinoma (HCC) • Liver Cancer • liver fibrosis • non-alcoholic fatty liver disease (NAFLD) • non-alcoholic steatohepatitis (NASH) • Obesity
ISBN-10 981-13-4213-X / 981134213X
ISBN-13 978-981-13-4213-4 / 9789811342134
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Diagnostik, Differenzialdiagnostik, Therapieansätze

von Frank Fischbach; Katharina Fischbach

Buch (2016)
Thieme (Verlag)
CHF 148,80